Literature DB >> 1548513

Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population.

M Markman, W Hoskins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1548513     DOI： 10.1200/JCO.1992.10.4.513

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  26 in total

Review 1.  Salvage therapy for ovarian cancer.

Authors:  A A Garcia
Journal:  Curr Oncol Rep       Date:  1999-09       Impact factor: 5.075

2.  Cyclosporin A reverses chemoresistance in patients with gynecologic malignancies.

Authors:  A K Sood; J I Sorosky; R C Squatrito; J S Skilling; B Anderson; R E Buller
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

3.  Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Authors:  Michelle L Harrison; Martin E Gore; David Spriggs; Stan Kaye; Alexia Iasonos; Martee Hensley; Carol Aghajanian; Ennapadam Venkatraman; Paul Sabbatini
Journal:  Gynecol Oncol       Date:  2007-07-05       Impact factor: 5.482

4.  [Therapeutic standards for ovarian cancer].

Authors:  J Pfisterer; A du Bois
Journal:  Pathologe       Date:  2007-05       Impact factor: 1.011

Review 5.  Second-line and subsequent therapy for ovarian carcinoma.

Authors:  Prema P Peethambaram; Harry J Long
Journal:  Curr Oncol Rep       Date:  2002-03       Impact factor: 5.075

Review 6.  'BRCAness' and its implications for platinum action in gynecologic cancer.

Authors:  Franco Muggia; Tamar Safra
Journal:  Anticancer Res       Date:  2014-02       Impact factor: 2.480

7.  Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.

Authors:  Kevin H Eng; Bret M Hanlon; William H Bradley; J Brian Szender
Journal:  Gynecol Oncol       Date:  2015-09-14       Impact factor: 5.482

Review 8.  Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.

Authors:  C R Lee; D Faulds
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

9.  Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancer.

Authors:  M Markman; T Hakes; B Reichman; J Curtin; R Barakat; S Rubin; W Jones; J L Lewis; L Almadrones; W Hoskins
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

10.  Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group.

Authors:  I Ray-Coquard; B Weber; J Cretin; Z Haddad-Guichard; E Lévy; A C Hardy-Bessard; M C Gouttebel; J-F Geay; A Aleba; H Orfeuvre; C Agostini; J Provencal; J M Ferrero; D Fric; N Dohollou; D Paraiso; J Salvat; E Pujade-Lauraine
Journal:  Br J Cancer       Date:  2009-02-03       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.